Psyence Biomedical logo
Psyence Biomedical
PBM | NASDAQ
Chart Builder DCF Calculator
$2.83
-$0.31 (-10.02%)
At close: Nov 16, 2026, 4:00 PM ET
$2.83
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Psyence Biomedical Company Profile

Company profile explained

Company Profile

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

Key Executives

Name Position
Jody Aufrichtig Co-Founder, Executive Chairman & Chief Executive Officer
Neil Maresky Global Head of Clinical Development
Taryn Vos General Counsel
Warwick Ron Corden-Lloyd CFO & Director

Latest SEC Filings

Date Type Title
Oct 21, 2026 6-K Filing
Oct 15, 2026 SC 13D/A [Amend] Filing
Oct 05, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 05, 2026 6-K Filing
Sep 28, 2026 6-K Filing
Sep 23, 2026 6-K Filing
Sep 14, 2026 6-K Filing
Sep 01, 2026 EFFECT Filing
Aug 26, 2026 S-8 Filing
Aug 26, 2026 F-3 Filing
View All SEC Filings ➞
Psyence Biomedical
Psyence Biomedical logo
Country Canada
IPO Date Dec 10, 2021
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Jody Aufrichtig

Contact Details

121 Richmond Street West Toronto, ON M5H 2K1 Canada

Stock Details

Ticker Symbol PBM
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001985062
CUSIP Number 74449F407
ISIN Number CA74449F4078
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.